<DOC>
	<DOC>NCT01660620</DOC>
	<brief_summary>We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.</brief_summary>
	<brief_title>Topical Betaxolol for the Prevention of Retinopathy of Prematurity</brief_title>
	<detailed_description>The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy of Prematurity</mesh_term>
	<mesh_term>Betaxolol</mesh_term>
	<criteria>&lt;1251 grms birth weight ocular defect</criteria>
	<gender>All</gender>
	<minimum_age>32 Weeks</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>betaxolol/ retinopathy of prematurity</keyword>
</DOC>